<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269397</url>
  </required_header>
  <id_info>
    <org_study_id>817914</org_study_id>
    <nct_id>NCT02269397</nct_id>
  </id_info>
  <brief_title>Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures</brief_title>
  <official_title>Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognizance Biomarkers, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cognizance Biomarkers, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this observational study is to establish the accuracy of CNS-specific&#xD;
      Assay for Recurrent Paroxysmal Events (CARPE) as a diagnostic blood test for epilepsy. The&#xD;
      target population is patients who have been newly referred to the Penn Epilepsy Center or&#xD;
      patients who are admitted to HUP for continuous video EEG monitoring. (Subjects without an&#xD;
      epilepsy diagnosis will be included.) Subjects will be asked to provide consent, agree to&#xD;
      allow the study team to collect information from their medical record, and to provide at&#xD;
      least one blood sample.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">December 6, 2018</completion_date>
  <primary_completion_date type="Actual">July 14, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epilepsy diagnosis (CARPE) blood test for determining the presence of epilepsy ad in doing so, determine the threshold for diagnosis</measure>
    <time_frame>2 years</time_frame>
    <description>Epilepsy diagnosis determined by three epileptologist's review of subject's medical records</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">371</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Individuals with suspected epilepsy</arm_group_label>
    <description>The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Subjects will be asked to give blood for evaluation of a diagnostic blood test for epilepsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged 12 years and older who are attending their first visit to the University of&#xD;
        Pennsylvania's Epilepsy Center for diagnostic purposes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female patients aged 12 and older&#xD;
&#xD;
          -  Evaluation in at least one of the following settings:&#xD;
&#xD;
          -  Newly referred to the University of Pennsylvania Penn Epilepsy Center. These patients&#xD;
             may not have completed any diagnostic evaluation at Penn, other than an initial&#xD;
             physician consultation, prior to enrollment and must agree to allow the study team to&#xD;
             collect records regarding their diagnostic evaluations (including EEG). Diagnostic&#xD;
             evaluations may take place at Penn or outside sites&#xD;
&#xD;
          -  All patients who are admitted to the University of Pennsylvania for continuous video&#xD;
             EEG (cVEEG) monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator or the patients neurologist, are&#xD;
             unable to give Informed Consent due to mental impairment or any other reason AND do&#xD;
             not have a LAR who can give Informed Consent on their behalf. Patients aged 12-17&#xD;
             (inclusive) must provide assent if they are mentally capable of doing so, and must&#xD;
             also have a caregiver who provides Informed Consent on their behalf&#xD;
&#xD;
          -  Patients who, in the opinion of their neurologist at the University of Pennsylvania,&#xD;
             are not good candidates for donating blood for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Crino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cognizance Biomarkers, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Seizures</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02269397/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02269397/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>October 28, 2019</submitted>
    <returned>November 15, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

